• Explore /
  • Poster
  • / Adjuvant infigratinib as targeted therapy for patients with muscle-invasive urothelial carcinoma harboring susceptible<em> FGFR3 </em>genetic alterations: A randomized, double-blind, placebo-controlled, phase 3 trial (PROOF 302).

Adjuvant infigratinib as targeted therapy for patients with muscle-invasive urothelial carcinoma harboring susceptible FGFR3 genetic alterations: A randomized, double-blind, placebo-controlled, phase 3 trial (PROOF 302).

Abstract Poster

Authors

Suzanne Cole

Suzanne Cole

Harold C. Simmons Comprehensive Cancer Center, Dallas, TX

Suzanne Cole , Siamak Daneshmand , Shilpa Gupta , Elan Diamond , Viraj A. Master , Florian Roghmann , Maria De Santis , Raj Satkunasivam , Gautam Jayram , Giuseppe Fornarini , Pierre Freres , Maria Jose Mendez-Vidal , Srikala S. Sridhar , Petros Grivas , Joaquim Bellmunt , Sijian Ge , Corina Andresen , Sumanta K. Pal , Seth P. Lerner

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Genitourinary Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session B: Urothelial Carcinoma

Track

Urothelial Carcinoma

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT04197986

Citation

J Clin Oncol 40, 2022 (suppl 6; abstr TPS580)

DOI

10.1200/JCO.2022.40.6_suppl.TPS580

Abstract #

TPS580

Poster Bd #

L12

Abstract Disclosures

Similar Posters

First Author: Siamak Daneshmand

First Author: Sumanta K. Pal

First Author: Petros Grivas

First Author: Yung Lyou